Trial Profile
A Phase I, Randomized, Single-Blind, Placebo Controlled Study to Assess the Safety, Tolerability and Pharmacodynamics Of AZD8601 After Single Dose Administration to Male Patients With Type II Diabetes Mellitus (T2DM)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Feb 2019
Price :
$35
*
At a glance
- Drugs AZD 8601 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 20 Feb 2019 According to a Moderna Therapeutics media release, data from this study is published in Nature Communications.
- 20 Feb 2019 Results published in the Moderna Therapeutics Media Release
- 08 Jan 2018 According to a Moderna Therapeutics media release, data from the study is expected to be presented at a scientific congress and published in 2018.